drugset / Trial / NCT00811356

A First Time in Human Study in Healthy Volunteers to Investigate a New Medicine to Treat Malaria

NCT00811356

Phase 1 Terminated 12 enrolled GlaxoSmithKline
RandomizedCrossoverSingle-blindTreatment

Summary

The purpose of this study is to determine if the study drug (antimalarial medication) is safe when given to healthy subjects as a single dose or as repeated doses, to understand the effect of food on single doses of study drug and to determine if the study drug has an effect on other approved medications such as rosiglitazone and rosuvastatin.

Timeline

Start
2008-12-11
Primary completion
2009-03-30
Completion
2009-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK932121 Unknown
Subject Rosiglitazone Small molecule
Subject Rosuvastatin Small molecule

Indications